It served its purpose.
Nothing better was available.
But this method has a lot of problems:
Drawbacks of ddPCR + ELISA for AAV:
1. Up to 8 machines involved
2. A lot of room for operator error
3. Limited insight into partial genomes
Add all that together, and you get:
- Results with big error bars
- Insights that might not be true
- Little data on an increasingly important metric (partials)
This isn’t sustainable.
And we shouldn’t settle for that.
What the industry needs:
- A single platform device
- Minimal user involvement
- Full:partial:empty AAV ratios
That’s what the Tessie offers.
It’s a single device workflow that:
- Provides full:partial:empty ratios
- Delivers results in less than 4 hours
- Requires only 4uL of crude sample
For the first time, we’re showing it publicly.
Next week, at ASGCT, Booth #332.
(In behind ThermoFisher)
I’d love to give you a tour.
Not attending?
Let's arrange something.
Just shoot me a DM.
So remember…
You don’t have to settle for standards of the past.
A better way is now available.
And it can get you where you need to go faster.
#genetherapy #innovation #biotechnology #aav
Corporate Design, Corporate Photo, Branding – Geschäftsführender Gesellschafter bei Heine Warnecke Design
2wThank you so much for working with us 🤩